Vergelijking
GHRP-6 vs. Ipamorelin
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Groei
Groei
CAS-nr.
87616-84-0
170851-70-4
Molecuulmassa
873.02 g/mol
711.86 g/mol
Halfwaardetijd
0.4 h
2 h
Sequentie
His-D-Trp-Ala-Trp-D-Phe-Lys-NH2Aib-His-D-2-Nal-D-Phe-Lys-NH2Werkingsmechanisme
GHRP-6
GHRP-6 is a high-affinity agonist of the growth-hormone secretagogue receptor 1a (GHSR-1a) — the same receptor later shown to bind the endogenous hormone ghrelin. The identification of GHRP-6 as a pharmacological anchor led to cloning of GHSR in 1996 and the discovery of ghrelin itself in 1999. GHRP-6 stimulates pituitary GH secretion via a pathway independent of GHRH and can be combined synergistically with GHRH. Via GHSR in the hypothalamus it additionally activates NPY/AgRP neurons, producing an orexigenic (appetite-stimulating) effect in animal models.
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Bewijsbasis
Hoogste bewijs
Humane studie
Humane RCT
Studies
4
4
waarvan bij mensen
2
3
Geregistreerde effecten
4
3
Openstaande tegenstrijdigheden
1
1
Gedocumenteerde bijwerkingen
2
1
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between GHRP-6 and Ipamorelin?
- GHRP-6 is classified as "Groei", while Ipamorelin is classified as "Groei". GHRP-6: Synthetic hexapeptide that founded the class of growth-hormone-releasing peptides (GHRPs). Cyril Bowers identified GHRP-6 in the late 1970s as the first orally and parenterally active GH secretagogue with no structural similarity to GHRH. Never approved as a medicine; downstream analogs (GHRP-2, hexarelin, ipamorelin) were pursued clinically. Ipamorelin: Synthetic pentapeptide and selective growth-hormone secretagogue. Developed at Novo Nordisk in the 1990s as a pentapeptide GHRP successor; clinical development was discontinued after phase 2 (post-operative ileus). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, GHRP-6 or Ipamorelin?
- The highest available evidence level is "Humane studie" for GHRP-6 and "Humane RCT" for Ipamorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of GHRP-6 and Ipamorelin in Germany and the United States?
- Duitsland: GHRP-6 — Niet goedgekeurd, Ipamorelin — Niet goedgekeurd. Verenigde Staten: GHRP-6 — Niet goedgekeurd, Ipamorelin — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.